JHS Svendgaard Laboratories Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The JHS Svendgaard Laboratories Q2 results FY27 announcement is the next scheduled earnings event for JHS Svendgaard Laboratories Ltd., JHS Svendgaard Laboratories Ltd manufactures oral care and personal care products, including toothpaste, largely on a contract manufacturing basis for third-party and own brands.. The stock traded at Rs 8.56 on the NSE on 16 September 2026, down 2.62% from the previous close of Rs 8.79, about 38.4% below its 52-week high of Rs 13.90 and 36.7% above its 52-week low of Rs 6.26.

What makes the JHS Svendgaard Laboratories Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 22.28 crore of revenue and a loss of Rs 0.20 crore, while the most recent quarter on record, Q1 FY27, produced Rs 30.38 crore and a profit of Rs 1.09 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the JHS Svendgaard Laboratories Q2 Results FY27 Date?

The JHS Svendgaard Laboratories Q2 results date for FY27 is not confirmed. As of 16 September 2026, JHS Svendgaard Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the JHS Svendgaard Laboratories Q2 results date becomes public through that filing rather than through any advance announcement.

Also read – Eris Lifesciences Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The JHS Svendgaard Laboratories Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for JHS Svendgaard Laboratories.

JHS Svendgaard Laboratories Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the JHS Svendgaard Laboratories Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for JHS Svendgaard Laboratories. The JHS Svendgaard Laboratories Q2 results watchlist below is built from what the company has actually reported and disclosed.

JHS Svendgaard Laboratories Q2 results for the September 2026 quarter follow an uneven revenue pattern over the last five reported quarters. Revenue moved from Rs23.45 crore in Jun25 to Rs22.28 crore in Sep25, then Rs23.27 crore in Dec25, before jumping to Rs32.7 crore in Mar26 and easing slightly to Rs30.38 crore in Jun26. This is a micro-cap oral care and contract manufacturing business, and revenue bounced around a fairly narrow base for most of the period before the Mar26 and Jun26 step-up. As the market awaits JHS Svendgaard Laboratories Q2 results, this recent lift in revenue is worth noting, though it should be read alongside the company's history of inconsistent profitability. JHS Svendgaard Laboratories Q2 results for the September 2026 quarter will be an important data point given how erratic this company's recent quarters have been.

Operating margin and net profit at JHS Svendgaard have been distinctly erratic across the five quarters under review. Operating margin moved from 7.08% in Jun25 down to 4.08% in Sep25, recovered to 7.18% in Dec25, then turned negative at -5.02% in Mar26 alongside an operating loss of Rs1.64 crore, before recovering to 6.81% in Jun26. Net profit tells the same story: a small profit of Rs1.06 crore in Jun25, a net loss of Rs0.20 crore in Sep25, a profit of Rs0.79 crore in Dec25, a much larger net loss of Rs3.57 crore in Mar26, and a modest profit of Rs1.09 crore in Jun26. This pattern should be stated plainly: JHS Svendgaard Laboratories Q2 results have to be read against a company that is currently a marginal, loss-prone micro-cap rather than a steady earner, and JHS Svendgaard Laboratories Q2 results for the September 2026 quarter will show whether the Jun26 recovery can hold.

Valuation metrics for JHS Svendgaard reflect this inconsistent earnings history: trailing P/E is not meaningful given recent losses, book value is Rs20 against a current price of about Rs8.6, giving a price-to-book ratio near 0.43, and both return on equity (-1.11%) and return on capital employed (-0.78%) are negative on a trailing basis, with no dividend paid. The single biggest data-quality point here, and one that should not be softened, is that this is a micro-cap with a net loss in Sep25 and both an operating loss and a larger net loss in Mar26, making its recent profitability genuinely erratic rather than merely lumpy. Anyone following JHS Svendgaard Laboratories Q2 results for the September 2026 quarter should weigh this loss-prone recent history alongside the small Jun26 recovery. JHS Svendgaard Laboratories Q2 results carry more uncertainty than most companies in this set, and JHS Svendgaard Laboratories Q2 results will only be meaningful in the context of this fragile earnings base.

Check JHS Svendgaard Laboratories Ltd. Live Fundamentals on the Univest Screener

JHS Svendgaard Laboratories Q2 Results Preview: The Q1 FY27 Actuals It Builds On

JHS Svendgaard Laboratories Ltd. reported revenue of Rs 30.38 crore in Q1 FY27, up 29.55% from Rs 23.45 crore in Q1 FY26, and a profit of Rs 1.09 crore at the net level, up 2.83% from Rs 1.06 crore in Q1 FY26. These are reported actuals, not estimates.

Also read – Escorts Kubota Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Sequentially, revenue was down 7.09% over the March 2026 quarter figure of Rs 32.70 crore, and net profit was a swing from a loss of Rs 3.57 crore in Q4 FY26 to a profit of Rs 1.09 crore. Operating margin stood at 7.08% in Q1 FY27 against 4.08% in the September 2025 quarter, which is the comparison the JHS Svendgaard Laboratories Q2 results print will be read against.

Q2 FY26 Base: The Comparison JHS Svendgaard Laboratories Q2 Results FY27 Must Beat

JHS Svendgaard Laboratories Ltd. reported revenue of Rs 22.28 crore and a loss of Rs 0.20 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this JHS Svendgaard Laboratories Q2 results preview.

Because the base quarter itself was loss-making, a year-on-year percentage comparison of profit is not meaningful for JHS Svendgaard Laboratories. The more useful test in the JHS Svendgaard Laboratories Q2 results print is whether the company reports a profit at all, and how the income line of Rs 22.28 crore compares with the Rs 30.38 crore of the June 2026 quarter.

JHS Svendgaard Laboratories Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	22.28	(0.20)
Q3 FY26 (Dec 2025)	23.27	0.79
Q4 FY26 (Mar 2026)	32.70	(3.57)
Q1 FY27 (Jun 2026)	30.38	1.09

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this JHS Svendgaard Laboratories Q2 results preview uses.

Revenue across those four quarters ranged from Rs 22.28 crore to Rs 32.70 crore, and net profit from Rs 3.57 crore loss to Rs 1.09 crore. That spread is the honest context for the JHS Svendgaard Laboratories Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape JHS Svendgaard Laboratories Q2 Results FY27

The JHS Svendgaard Laboratories Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what JHS Svendgaard Laboratories has already reported.

Valuation Snapshot

JHS Svendgaard trades at around Rs8.56 to Rs8.64, well below its book value of Rs20, giving a price-to-book ratio of about 0.43. A trailing price-to-earnings ratio is not meaningful given the company's recent losses, and EPS is similarly not meaningful on a trailing basis. Return on equity stands at -1.11%, reflecting the erratic profitability of recent quarters, and the company pays no dividend, with a yield of 0.00%. These figures describe a micro-cap trading below book value with a currently negative return profile rather than a conventionally valued stock.

Technical and Price Context

JHS Svendgaard's 52-week range runs from Rs6.26 to Rs13.9, and the current price of around Rs8.56 sits above its 50-day moving average of Rs7.98 but below its 200-day moving average of Rs8.92, a mixed short and long-term trend picture. The relative strength index of 41.54 is in neutral to slightly weak territory, neither overbought nor oversold. The stock fell about 2.6% in the latest session, trading well off its 52-week high of Rs13.9 and closer to the lower half of its annual range.

Balance Sheet and Payout

JHS Svendgaard carries a debt-to-equity ratio of 0.09, a relatively low level of borrowings for a manufacturing business, which limits interest-cost pressure even during the loss-making quarters seen in this period. The company pays no dividend, with a yield of 0.00%, consistent with a micro-cap that has posted negative net profit in some recent quarters and needs to preserve cash. The combination of modest debt and no payout reflects a business still working to establish consistent profitability rather than one distributing surplus cash to shareholders.

JHS Svendgaard Laboratories Q2 Results FY27: Share Price and Valuation Going Into the Print

JHS Svendgaard Laboratories share price today is Rs 8.56 on the NSE, down Rs 0.23 or 2.62% from the previous close of Rs 8.79 on 16 September 2026, ahead of the JHS Svendgaard Laboratories Q2 results announcement.

Metric	Value (16 September 2026)
NSE Symbol	JHS
Current Market Price	Rs 8.56
52-Week High	Rs 13.90
52-Week Low	Rs 6.26
Market Capitalisation	Rs 75 crore
PE Ratio	Not meaningful on a trailing loss
PB Ratio	0.43
EPS (TTM)	Not meaningful on a trailing loss
Book Value per Share	Rs 20.00
Debt to Equity	0.09
Return on Equity	-1.11%
50-Day Moving Average	Rs 7.98
200-Day Moving Average	Rs 8.92
RSI (14)	41.54

The stock trades above its 50-day average of Rs 7.98 but below its 200-day average of Rs 8.92, with a 14-day RSI of 41.54. None of this is a view on where the shares go once the JHS Svendgaard Laboratories Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track JHS Svendgaard Laboratories Ltd. live price and quarterly earnings updates.

What Investors Should Watch When JHS Svendgaard Laboratories Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the JHS Svendgaard Laboratories Q2 results print in proportion.

1. Revenue against the Rs 22.28 crore reported in the September 2025 base quarter
2. Net profit against a loss of Rs 0.20 crore in that same quarter
3. Operating margin against 7.08% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the JHS Svendgaard Laboratories Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on JHS Svendgaard Laboratories Q2 Results FY27

The JHS Svendgaard Laboratories Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. JHS Svendgaard Laboratories Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the JHS Svendgaard Laboratories Q2 results FY27 print faces a base of Rs 22.28 crore in revenue and a loss of Rs 0.20 crore, with the most recent quarter having delivered Rs 30.38 crore and a profit of Rs 1.09 crore. No numerical estimate appears in this preview because no verified consensus figure exists for JHS Svendgaard Laboratories, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on JHS Svendgaard Laboratories Q2 Results FY27

What is the JHS Svendgaard Laboratories Q2 results date for FY27?

Ans. The JHS Svendgaard Laboratories Q2 results date for FY27 is not confirmed. JHS Svendgaard Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the JHS Svendgaard Laboratories Q2 results 2026 cover?

Ans. The JHS Svendgaard Laboratories Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. JHS Svendgaard Laboratories Ltd. reports revenue, operating profit and net profit for that period, and the JHS Svendgaard Laboratories Q2 results filing also carries the notes to the accounts.

What were the JHS Svendgaard Laboratories Q1 FY27 results?

Ans. JHS Svendgaard Laboratories Ltd. reported revenue of Rs 30.38 crore in Q1 FY27 and a profit of Rs 1.09 crore at the net level. Revenue was up 29.55% versus Q1 FY26 and net profit was up 2.83% from Rs 1.06 crore in Q1 FY26.

What were JHS Svendgaard Laboratories Q2 FY26 results in the September 2025 quarter?

Ans. JHS Svendgaard Laboratories Ltd. reported revenue of Rs 22.28 crore and a loss of Rs 0.20 crore in Q2 FY26. Operating margin was 4.08%. Those figures form the base for the JHS Svendgaard Laboratories Q2 results FY27 comparison.

What are the main JHS Svendgaard Laboratories Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The JHS Svendgaard Laboratories Q2 results expectations centre on revenue against the Rs 22.28 crore base, net profit against a loss of Rs 0.20 crore, operating margin against 7.08% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is JHS Svendgaard Laboratories share price today ahead of the Q2 earnings?

Ans. JHS Svendgaard Laboratories share price is Rs 8.56 on the NSE as of 16 September 2026, down 2.62% from Rs 8.79. The stock is about 38.4% below its 52-week high of Rs 13.90 and 36.7% above its 52-week low of Rs 6.26, at a market capitalisation of Rs 75 crore.

Is JHS Svendgaard Laboratories a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on JHS Svendgaard Laboratories Ltd. The stock trades at a price-to-book ratio of 0.43 with a return on equity of -1.11%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.